Loading...

Home
Stock
ELVN

ELVN News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ELVN News

Enliven Therapeutics Director Sells Shares Amid Rising Investor Sentiment

Jun 27 2026NASDAQ.COM

Enliven Therapeutics Director Sells Shares

Jun 27 2026Fool

Enliven Therapeutics Director Sells 10,000 Shares Amid 130% Stock Surge

Jun 27 2026Yahoo Finance

Orbimed Advisors Sells 860,123 Shares of Enliven Therapeutics

Jun 27 2026Fool

Orbimed Advisors Sells ELVN Shares Worth $39 Million

Jun 27 2026NASDAQ.COM

Orbimed Advisors Reduces Stake in Enliven Therapeutics

Jun 24 2026Fool

Orbimed Advisors Sells Shares in Enliven Therapeutics

Jun 24 2026NASDAQ.COM

Enliven Therapeutics Closes $460 Million Upsized Public Offering

Jun 15 2026Newsfilter

ELVN Events

Enliven Stock Rises 9.9% to $44.37

Enliven is up 9.9%, or $4.01 to $44.37.

Deal Size Increased to $400M

The deal size was increased to $400M in common stock from $250M in common stock. Jefferies, Goldman Sachs, Morgan Stanley and Barclays acted as joint book running managers for the offering.

ELVN Monitor News

Enliven Therapeutics Completes $400 Million Public Offering

Enliven Therapeutics Reports Positive Data for ELVN-001 in CML Trial

Enliven Therapeutics CMO sells shares amid market context

Enliven Therapeutics stock rises amid sector rotation

Enliven Therapeutics' ELVN-001 Gains Attention Amid Merck's Acquisition

Enliven Therapeutics' ELVN-001 Gains Attention Amid Merck's Acquisition

Mizuho raises target price for Enliven Therapeutics to $45

Enliven Therapeutics' ELVN-001 Shows Promising Trial Results

ELVN Earnings Analysis

No Data

No Data

People Also Watch